Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R
Preliminary Clinical Data with Cold/Hot Dosing Regimen Demonstrate Potential to Improve Therapeutic Index and Safety Profile
Company Prioritizing Cold/Hot Dosing Regimen in Phase 1 Trial; Cohort 2 in this Arm is Currently Enrolling
Data to be Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
Fusion to Host Conference Call Tomorrow, Tuesday, June 27th at 4:00 p.m. ET/3:00 p.m. CT
HAMILTON, ON and BOSTON, June 26, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of interim data from the do
